One To Watch

BioMarin Pharmaceutical

A global biotechnology company focused on discovering, developing and commercializing transformative medicines for people living with rare and genetically defined diseases. BioMarin applies genetic and genomic science to address conditions with significant unmet needs and a high burden of morbidity.

Company Overview

BioMarin Pharma is a leader in rare disease biotech, with a track record of pioneering enzyme replacement therapies and other targeted genetic medicines. The company’s commercial portfolio includes eight approved therapies for serious inherited conditions, and its pipeline spans clinical and preclinical programs informed by deep biology.

BioMarin’s strategy blends sustained execution of existing approvals with innovation in genetic and metabolic medicine, seeking to expand treatment options for patient populations that historically lacked effective therapies.

Headquarters and Global Presence

BioMarin is headquartered in San Rafael, California, United States. The company also maintains presence in the United States, Europe, Asia and other regions to support global clinical development and commercialization.

Founding and History

BioMarin was founded in 1997 and has since grown into a globally recognized rare disease biotechnology company. Its early innovation included enzyme replacement therapies for lysosomal storage disorders and metabolic conditions. Over time, BioMarin expanded into gene therapy and broader genetic medicine.

Notably, in December 2025 BioMarin announced an agreement to acquire Amicus Therapeutics for approximately $4.8 billion, a deal aimed at broadening its rare disease portfolio with additional commercial assets and pipeline programs.

Therapy Areas and Focus

BioMarin’s clinical and commercial activities center on rare and genetically defined diseases. Its key therapy areas include:

Rare metabolic disorders such as phenylketonuria (PKU)
Lysosomal storage disorders including mucopolysaccharidoses and Batten disease
Skeletal dysplasias like achondroplasia
Bleeding disorders including hemophilia A
Non-oncology hematology and other genetic conditions explored in its pipeline

Technology Platforms and Modalities

BioMarin’s innovation spans multiple modalities:

Enzyme replacement therapies for inherited metabolic and storage diseases
Gene therapy, including an adeno-associated viral vector for severe hemophilia A
Small molecules and other biologics tailored to genetic disease mechanisms
Discovery and clinical development programs in central nervous system, cardiovascular, metabolic and musculoskeletal biology

Key Personnel

Alexander Hardy, Chief Executive Officer and President
Brian R. Mueller, Executive Vice President and Chief Financial Officer

Strategic Partnerships and Business Development

BioMarin pursues strategic acquisitions and collaborations to expand its impact. The announced acquisition of Amicus Therapeutics in 2025 is intended to strengthen its rare disease portfolio with complementary approved products and pipeline assets, and follows prior bolt-on deals such as its purchase of Inozyme Pharma to add early-stage programs.

The company also engages with academic and industry partners to drive translational science and broaden development capacity across multiple therapeutic areas.

FAQ Section

BioMarin is a rare disease biotechnology company that develops and commercializes medicines for genetically defined conditions, including enzyme therapies and gene therapies.

BioMarin prioritizes inherited rare diseases, including metabolic, musculoskeletal, hematologic and other genetically driven conditions.

BioMarin’s commercial products include therapies such as Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq, Vimizim, Roctavian and Voxzogo for conditions spanning lysosomal storage disorders, PKU, hemophilia A and skeletal dysplasia.

The planned acquisition of Amicus Therapeutics is intended to broaden BioMarin’s rare disease portfolio with approved therapies and pipeline assets, enhancing its commercial footprint and diversifying revenue.

BioMarin advances next-generation genetic medicines through gene therapy programs, investigational small molecules and biologics across rare disease mechanisms, aiming to expand indications and patient reach.

Important watchpoints include late-stage data readouts for pipeline candidates across its rare disease focus areas, regulatory submissions for new indications, and successful integration of acquired assets into development and commercial plans.

Milestones include regulatory filings and approvals for pipeline programs, demonstration of clinical benefit across rare indications, and completion of strategic acquisitions such as the Amicus deal to strengthen long-term growth prospects.

Want to Update your Company's Profile?